Drug search by name

Thioplex and Myelosuppression

Result of checking the interaction of drug Thioplex and disease Myelosuppression for safety when used together.

Check result:

Thioplex <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Thiotepa induces dose-related myelosuppression. Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

References:

Watkins WE, Kozak JA, Flanagan MJ "Severe pancytopenia associated with the use of intravesical thio- TEPA." J Urol 98 (1967): 470-1
Agnelli G, de Cunto M, Gresele P, del Favero A "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa." Postgrad Med J 58 (1982): 380-1
Soloway MS, Ford KS "Thiotepa-induced myelosuppression: review of 670 bladder instillations." J Urol 130 (1983): 889-91
Hollister D Jr, Coleman M "Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma." JAMA 244 (1980): 2065-7

Thioplex

Generic Name: thiotepa

Brand Name: Thioplex, Tepadina

Synonyms: n.a.

What is Thioplex?